# Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma

> **NCT02512692** · NA · TERMINATED · sponsor: **Medical University of South Carolina** · enrollment: 6 (actual)

## Conditions studied

- Intrahepatic Cholangiocarcinoma

## Interventions

- **DEVICE:** SIR-Spheres microspheres (Yttrium-90 Microspheres)
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT02512692
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07-21
- **Primary completion:** 2021-03-19
- **Final completion:** 2021-03-19
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Enrollment closed by internal scientific review committee due to slow accrual.
- **Last updated:** 2024-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02512692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02512692, "Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02512692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*